… normal brain function. However, misfolded a-synuclein can form the aggregated fibrils that contribute to Parkinson’s … RT-QuIC as a potential PD biomarker tool, we propose blind testing of SMG and CSF samples from S4 subjects. Hypothesis: …  This study seeks to determine the clinical utility and to compare the performance of our α- synuclein RT-QuIC assay …

… Study Rationale: MicroRNAs (miRNAs) are small regulatory RNAs controlling gene expression. We have recently … motor symptoms (Fernández-Santiago et al. Ann Neurol 2015). Here we aim to expand previous association findings by … levels in a cohort of subjects at-risk to develop PD encompassing healthy individuals carrying the G2019S mutation …

… Study Rationale: Parkinson’s disease is accompanied by a loss of chemical signaling molecules in the … dopamine are lost in both the gut and in the brain, leading to gastrointestinal and movement complications. The purpose … Additionally, this study may provide novel biological targets for Parkinson’s disease if one or more of the analyzed …

… disease (PD) organizations from around the world have come together as Clinical Trial Recruitment Community Partners to … important, 'someone else' would be there to participate. However, that 'someone else' is me and every PD patient, …

… Study Rationale:  One common familial inherited form of Parkinson’s disease (PD) … encodes the protein alpha-synuclein. Alpha-synuclein forms toxic aggregates in the brains of people with PD. This study … there are differences in the health of the cells as well as how they may differ functionally. Impact on …

… dismutases and catalase. The goal of this proposal is to determine if a newly developed glyoxylate (AEOL112) … A newly developed glyoxylate series of metalloporphyrin compounds designed to penetrate the blood brain barrier have … glyoxylate class of metalloporphyrins to identify the best drug candidate for clinical development for PD. Relevance to …